Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068198 · ClinicalTrials.gov registry record · Phase 1
Human Immune Responses Smallpox
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00068198 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 45 participants.
The verdict
NCT00068198, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to attempt to identify the immune response of healthy adults to an investigational dilution of the Dryvax smallpox vaccine. In addition, we will try to determine whether certain genetic characteristics influence the size of the sore around the vaccination site, and use blood samples from subjects in the study to make a new form of antibody that could be given to people with vaccine side effects.
Interventions
- BIOLOGICAL Dryvax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068198
The ClinicalTrials.gov registry entry for NCT00068198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dryvax is the first listed.
NCT00068198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068198 about?
NCT00068198 is a clinical study titled "Human Immune Responses Smallpox". The purpose of this study is to attempt to identify the immune response of healthy adults to an investigational dilution of the Dryvax smallpox vaccine. In addition, we will try to determine whether certain genetic characteristics influence the size of the sore around the vaccination site, and use b...
What is the current status of trial NCT00068198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00068198?
The interventions under investigation include: Dryvax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00068198?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.